Results 111 to 120 of about 31,621 (232)

Reappraisal of Plasmapheresis as a Supportive Measure in a Patient with Hepatic Failure after Major Hepatectomy [PDF]

open access: yes, 2007
Major resection of cirrhotic livers can result in hepatic failure, but no supportive treatment has been found to be generally effective. We successfully treated a 63-year-old woman with post-hepatectomy liver failure with plasmapheresis.
Tae-Yong Ha   +4 more
core   +1 more source

Real‐World Use of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Early and Long‐Term Clinical, Renal, and Patient‐Reported Outcomes in an Italian Rheumatology–Nephrology Network

open access: yesACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective Complement activation, particularly through the C5a–C5a receptor axis, plays a pivotal role in the pathogenesis of antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and may represent an important therapeutic target. Avacopan, an oral C5a receptor antagonist, was the first therapy targeting this pathway to enter in clinical ...
Luca Quartuccio   +33 more
wiley   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Plasmapheresis

open access: yesDeutsches Ärzteblatt international, 2021
openaire   +3 more sources

Safety and Feasibility of Magnetic Separation‐Based Blood Purification

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 10, October 2026.
We present the preclinical biological safety and translational feasibility of a magnetic nanoparticle‐based extracorporeal blood purification platform for removal of disease‐causing blood factors. ISO 10993‐compliant studies and exaggerated worst‐case exposure models demonstrate efficient nanoparticle extraction (≥99.9%), favorable biocompatibility ...
Carlos A. Mora   +11 more
wiley   +1 more source

Plasmapheresis in a patient with scleromyxedema.

open access: yes, 1987
We describe a patient with progressive scleromyxedema who failed to respond to previously described treatment modalities. A trial of plasmapheresis was initiated, but after an initial promising response, his disease continued to progress.
Lookingbill, D P, Westheim, A I
core   +1 more source

Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC0–12 in Kidney Transplant Recipients

open access: yes, 2019
Background: Mycophenolic acid (MPA), a crucial immunosuppressive drug, and plasmapheresis, an effective immunoreduction method, are simultaneously used for the management of various immune-related diseases, including kidney transplantation.
Kearkiat Praditpornsilpa   +10 more
core   +1 more source

Therapeutic plasmapheresis in patients with severe hyperthyroidism in whom antithyroid drugs are contraindicated

open access: yes, 2004
Four patients with Graves' disease in whom antithyroid drugs could not be used were treated by plasmapheresis preoperatively. On admission all patients had severe hyperthyroidism.
Gul, Nurdan   +5 more
core   +1 more source

plasmapheresis

open access: yes
Citation: 'plasmapheresis' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13579 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +2 more sources

Home - About - Disclaimer - Privacy